Dyskinesia - Pipeline Review, H1 2016

Published: Mar, 2016 | Pages: 183 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Dyskinesia - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Dyskinesia - Pipeline Review, H1 2016', provides an overview of the Dyskinesia pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Dyskinesia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Dyskinesia
- The report reviews pipeline therapeutics for Dyskinesia by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Dyskinesia therapeutics and enlists all their major and minor projects
- The report assesses Dyskinesia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Dyskinesia

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Dyskinesia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Dyskinesia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Dyskinesia Overview 8
Therapeutics Development 9
Pipeline Products for Dyskinesia - Overview 9
Pipeline Products for Dyskinesia - Comparative Analysis 10
Dyskinesia - Therapeutics under Development by Companies 11
Dyskinesia - Therapeutics under Investigation by Universities/Institutes 13
Dyskinesia - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Dyskinesia - Products under Development by Companies 17
Dyskinesia - Products under Investigation by Universities/Institutes 20
Dyskinesia - Companies Involved in Therapeutics Development 21
Adamas Pharmaceuticals, Inc. 21
Addex Therapeutics Ltd 22
Advicenne Pharma 23
Amarantus Bioscience Holdings, Inc. 24
Astraea Therapeutics, LLC 25
Bionomics Limited 26
Catalyst Biosciences, Inc. 27
Catalyst Pharmaceutical Partners, Inc. 28
Clevexel Pharma SAS 29
Contera Pharma ApS 30
EpiVax, Inc. 31
Heptares Therapeutics Limited 32
Hua Medicine Ltd. 33
Integrative Research Laboratories Sweden AB 34
Ipsen S.A. 35
Merz Pharma GmbH & Co. KgaA 36
MitoDys Therapeutics Limited 37
Neurim Pharmaceuticals Ltd 38
Neurocrine Biosciences, Inc. 39
Neurolixis Inc. 40
Osmotica Pharmaceutical Corp. 41
Otsuka Holdings Co., Ltd. 42
Phenomenome Discoveries, Inc. 43
Revance Therapeutics, Inc. 44
Sage Therapeutics, Inc. 45
Santhera Pharmaceuticals Holding AG 46
SciFluor Life Sciences, LLC 47
SOM Innovation Biotech SL 48
Synchroneuron Inc. 49
Teva Pharmaceutical Industries Limited 50
Dyskinesia - Therapeutics Assessment 51
Assessment by Monotherapy Products 51
Assessment by Combination Products 52
Assessment by Target 53
Assessment by Mechanism of Action 56
Assessment by Route of Administration 58
Assessment by Molecule Type 60
Drug Profiles 62
(dextromethorphan + quinidine sulfate) - Drug Profile 62
A2M-13677 - Drug Profile 64
abobotulinumtoxin A - Drug Profile 65
abobotulinumtoxin A next generation - Drug Profile 67
acamprosate calcium SR - Drug Profile 68
amantadine hydrochloride ER - Drug Profile 70
amantadine hydrochloride ER - Drug Profile 72
AT-127 - Drug Profile 73
AT-326 - Drug Profile 74
AT-403 - Drug Profile 75
befiradol - Drug Profile 76
CPP-115 - Drug Profile 78
CVXL-0107 - Drug Profile 80
daxibotulinumtoxin A - Drug Profile 81
deutetrabenazine ER - Drug Profile 83
dipraglurant ER - Drug Profile 85
dipraglurant IR - Drug Profile 86
Drug for Dyskinesia - Drug Profile 88
Drugs for Dyskinesia - Drug Profile 89
Drugs for Tardive Dyskinesia - Drug Profile 90
eltoprazine - Drug Profile 91
fipamezole - Drug Profile 94
HTL-14242 - Drug Profile 96
IRL-790 - Drug Profile 97
JM-010 - Drug Profile 98
MLR-1019 - Drug Profile 100
MRZ-8676 - Drug Profile 101
NBI-640756 - Drug Profile 102
Neu-120 - Drug Profile 103
Neu-240 - Drug Profile 104
onabotulinumtoxin A - Drug Profile 105
PEUN-3 - Drug Profile 106
PPI-1011 - Drug Profile 107
RT-002 - Drug Profile 108
SAGE-217 - Drug Profile 109
sepranolone - Drug Profile 110
SK-609 - Drug Profile 113
Small Molecule for Dyskinesia - Drug Profile 114
Small Molecule for Dyskinesia and Hyperkinesia - Drug Profile 115
Small Molecules for CNS Disorders - Drug Profile 116
Small Molecules for Neurodegenerative Disease - Drug Profile 117
Small Molecules to Antagonize M1 Muscarinic Acetylcholine Receptor for Dystonia - Drug Profile 118
Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders - Drug Profile 119
Small Molecules to Antagonize mGluR5 for Dyskinesia - Drug Profile 120
SOM-3355 - Drug Profile 121
TC-8831 - Drug Profile 122
tetrabenazine - Drug Profile 123
valbenazine tosylate - Drug Profile 124
VU-0431316 - Drug Profile 126
Dyskinesia - Recent Pipeline Updates 127
Dyskinesia - Dormant Projects 164
Dyskinesia - Discontinued Products 167
Dyskinesia - Product Development Milestones 168
Featured News & Press Releases 168
Appendix 178
Methodology 178
Coverage 178
Secondary Research 178
Primary Research 178
Expert Panel Validation 178
Contact Us 178
Disclaimer 179

List of Tables

Number of Products under Development for Dyskinesia, H1 2016 13
Number of Products under Development for Dyskinesia - Comparative Analysis, H1 2016 14
Number of Products under Development by Companies, H1 2016 15
Number of Products under Development by Companies, H1 2016 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H1 2016 17
Comparative Analysis by Late Stage Development, H1 2016 18
Comparative Analysis by Clinical Stage Development, H1 2016 19
Comparative Analysis by Early Stage Development, H1 2016 20
Products under Development by Companies, H1 2016 21
Products under Development by Companies, H1 2016 (Contd..1) 22
Products under Development by Companies, H1 2016 (Contd..2) 23
Products under Investigation by Universities/Institutes, H1 2016 24
Dyskinesia - Pipeline by Adamas Pharmaceuticals, Inc., H1 2016 25
Dyskinesia - Pipeline by Addex Therapeutics Ltd, H1 2016 26
Dyskinesia - Pipeline by Advicenne Pharma, H1 2016 27
Dyskinesia - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2016 28
Dyskinesia - Pipeline by Astraea Therapeutics, LLC, H1 2016 29
Dyskinesia - Pipeline by Bionomics Limited, H1 2016 30
Dyskinesia - Pipeline by Catalyst Biosciences, Inc., H1 2016 31
Dyskinesia - Pipeline by Catalyst Pharmaceutical Partners, Inc., H1 2016 32
Dyskinesia - Pipeline by Clevexel Pharma SAS, H1 2016 33
Dyskinesia - Pipeline by Contera Pharma ApS, H1 2016 34
Dyskinesia - Pipeline by EpiVax, Inc., H1 2016 35
Dyskinesia - Pipeline by Heptares Therapeutics Limited, H1 2016 36
Dyskinesia - Pipeline by Hua Medicine Ltd., H1 2016 37
Dyskinesia - Pipeline by Integrative Research Laboratories Sweden AB, H1 2016 38
Dyskinesia - Pipeline by Ipsen S.A., H1 2016 39
Dyskinesia - Pipeline by Merz Pharma GmbH & Co. KgaA, H1 2016 40
Dyskinesia - Pipeline by MitoDys Therapeutics Limited, H1 2016 41
Dyskinesia - Pipeline by Neurim Pharmaceuticals Ltd, H1 2016 42
Dyskinesia - Pipeline by Neurocrine Biosciences, Inc., H1 2016 43
Dyskinesia - Pipeline by Neurolixis Inc., H1 2016 44
Dyskinesia - Pipeline by Osmotica Pharmaceutical Corp., H1 2016 45
Dyskinesia - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 46
Dyskinesia - Pipeline by Phenomenome Discoveries, Inc., H1 2016 47
Dyskinesia - Pipeline by Revance Therapeutics, Inc., H1 2016 48
Dyskinesia - Pipeline by Sage Therapeutics, Inc., H1 2016 49
Dyskinesia - Pipeline by Santhera Pharmaceuticals Holding AG, H1 2016 50
Dyskinesia - Pipeline by SciFluor Life Sciences, LLC, H1 2016 51
Dyskinesia - Pipeline by SOM Innovation Biotech SL, H1 2016 52
Dyskinesia - Pipeline by Synchroneuron Inc., H1 2016 53
Dyskinesia - Pipeline by Teva Pharmaceutical Industries Limited, H1 2016 54
Assessment by Monotherapy Products, H1 2016 55
Assessment by Combination Products, H1 2016 56
Number of Products by Stage and Target, H1 2016 58
Number of Products by Stage and Mechanism of Action, H1 2016 61
Number of Products by Stage and Route of Administration, H1 2016 63
Number of Products by Stage and Molecule Type, H1 2016 65
Dyskinesia Therapeutics - Recent Pipeline Updates, H1 2016 131
Dyskinesia - Dormant Projects, H1 2016 168
Dyskinesia - Dormant Projects (Contd..1), H1 2016 169
Dyskinesia - Dormant Projects (Contd..2), H1 2016 170
Dyskinesia - Discontinued Products, H1 2016 171